Hims & Hers Health, Inc. (NYSE:HIMS) Encounters Regulatory Headwinds, Near-Term Volatility Ahead

Regulatory scrutiny and shrinking margin momentum pressure the company’s immediate outlook, while a strong cash balance moderates liquidity risk. Technicals skew bearish but metric-based upside potential exists if momentum indicators reverse.

Recent News

On August 14, 2025, reports indicated the U.S. Federal Trade Commission has been investigating Hims & Hers over advertising and subscription cancellation practices. On September 16, 2025, the U.S. Food and Drug Administration issued a warning letter citing misleading claims around compounded GLP-1 and weight-loss products. The company’s CEO executed a large stock sale in mid-August, disclosed in regulatory filings.

Technical Analysis

ADX at 18.36 signals no established trend, which increases the likelihood of short-term swings rather than a sustained directional move; this elevates the relevance of headlines in driving price action and aligns with the expectation of near-term volatility.

Directional indicators show bearish alignment: DI+ sits at 19.87 and trends decreasing while DI- at 32.03 has completed a dip-and-reverse, which registers as bearish pressure. Together these suggest sellers currently exert more directional force than buyers relative to the prior range.

MACD stands at -2.74 with a declining MACD_trend and a signal line at -1.86; the MACD below its signal line confirms negative momentum and reduces the likelihood of a momentum-led upside until MACD turns higher or crosses above the signal line.

MRO at -7.48 records a negative reading, indicating price sits below the model target and therefore contains latent upside potential; the MRO trend decreasing increases the amplitude of that mispricing, implying more room for mean reversion if momentum shifts.

RSI at 41.57 and decreasing points to weakening internals without reaching deep oversold conditions, suggesting rallies may encounter resistance until internal momentum indicators stabilize or reverse upward.

Price relationships bias to the downside: the close at $41.03 sits below the 12-day EMA ($45.10, decreasing), below the 26-day EMA ($48.20), and below the 200-day average ($46.74), reinforcing a bearish technical posture. The super trend upper band at $48.44 and Ichimoku components (TenkanSen $45.35, KijunSen $52.32) also lie above price, creating multiple overhead resistance levels.

Bollinger placement shows price near the lower band (between the 1x lower $42.56 and 2x lower $39.46), a location that can produce short-term mean-reversion bounces but, given the other bearish indicators, such bounces may fail without a momentum shift. Elevated short- and medium-term betas (42-day 2.88, 52-week 2.49) imply outsized reaction to market moves and headlines, amplifying swing risk.

 


Fundamental Analysis

Revenue totaled $544,833,000 while net income reached $42,505,000; gross margin remains strong at 76.39%, supporting cash profitability on product sales. Operating income (EBIT) equals $26,723,000 and operating margin stands at 4.91%.

EBIT margin of 4.91% sits below the industry peer mean of 7.36% but above the industry peer median of 2.77%, indicating performance better than the typical peer yet short of the peer average. Sequentially, EBIT margin declined QoQ by 50.35% while improving YoY by 40.38%, signaling volatile margin dynamics tied to recent product mix and operational changes.

Earnings per share came in at $0.06 against an estimate of $0.10, a miss of $0.04 or 40%, which compresses near-term investor sentiment despite positive YoY earnings growth metrics. WMDST’s dataset shows earnings growth at 45% with earningsGrowthYoY presented at 125%, reflecting strong multi-period improvement from the prior-year base.

Liquidity and leverage present a mixed picture: cash and short-term investments of $1,144,615,000 produce a cash ratio of 4.20 and a current ratio of 4.98, buffering working-capital needs. Total debt stands at $1,044,388,000 with debt-to-equity at 185.60% and debt-to-EBITDA at 28.08, reflecting elevated leverage relative to operating earnings despite substantial cash holdings. Interest coverage at 16.89 indicates the company currently covers interest expense comfortably.

Valuation metrics point to premium market pricing: P/E at 176.79, P/S at 20.27, and price-to-book at 19.63. Free cash flow remains negative at -$69,432,000 and free-cash-flow yield records -0.63%, which, combined with an enterprise multiple near 294, supports the WMDST valuation conclusion that the stock trades over-valued. The high multiples coexist with strong gross margins and a large cash balance, which reduce insolvency risk but do not reconcile the premium multiples with current free cash flow generation.

In sum, fundamentals show durable gross profitability and a strong cash cushion but volatile revenue/margin dynamics, a meaningful EPS miss, negative free cash flow, and stretched valuation multiples; WMDST values the stock as over-valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-11-03
NEXT REPORT DATE: 2026-02-02
CASH FLOW  Begin Period Cash Flow 275.0 M
 Operating Cash Flow -19.12 M
 Capital Expenditures -50.31 M
 Change In Working Capital -101.53 M
 Dividends Paid
 Cash Flow Delta 850.0 M
 End Period Cash Flow 1.1 B
 
INCOME STATEMENT REVENUE
 Total Revenue 544.8 M
 Forward Revenue 83.2 M
COSTS
 Cost Of Revenue 128.6 M
 Depreciation 10.5 M
 Depreciation and Amortization 10.5 M
 Research and Development 37.8 M
 Total Operating Expenses 518.1 M
PROFITABILITY
 Gross Profit 416.2 M
 EBITDA 37.2 M
 EBIT 26.7 M
 Operating Income 26.7 M
 Interest Income
 Interest Expense
 Net Interest Income
 Income Before Tax 32.9 M
 Tax Provision -9.65 M
 Tax Rate 21.0 %
 Net Income 42.5 M
 Net Income From Continuing Operations 42.5 M
EARNINGS
 EPS Estimate 0.10
 EPS Actual 0.06
 EPS Difference -0.04
 EPS Surprise -40.0 %
 Forward EPS 0.12
 
BALANCE SHEET ASSETS
 Total Assets 1.9 B
 Intangible Assets 158.4 M
 Net Tangible Assets 404.3 M
 Total Current Assets 1.4 B
 Cash and Short-Term Investments 1.1 B
 Cash 1.1 B
 Net Receivables 6.7 M
 Inventory 141.8 M
 Long-Term Investments 2.2 M
LIABILITIES
 Accounts Payable 105.0 M
 Short-Term Debt
 Total Current Liabilities 272.2 M
 Net Debt
 Total Debt 1.0 B
 Total Liabilities 1.3 B
EQUITY
 Total Equity 562.7 M
 Retained Earnings -150.15 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 2.49
 Shares Outstanding 225.759 M
 Revenue Per-Share 2.41
VALUATION
 Market Capitalization 11.0 B
 Enterprise Value 10.9 B
 Enterprise Multiple 294.258
Enterprise Multiple QoQ 177.205 %
Enterprise Multiple YoY 7.715 %
Enterprise Multiple IPRWA HIMS: 294.258
high: 206.444
mean: 52.868
median: 47.277
low: -71.066
 EV/R 20.085
CAPITAL STRUCTURE
 Asset To Equity 3.337
 Asset To Liability 1.428
 Debt To Capital 0.65
 Debt To Assets 0.556
Debt To Assets QoQ 682.555 %
Debt To Assets YoY 8080.0 %
Debt To Assets IPRWA high: 1.03
HIMS: 0.556
mean: 0.323
median: 0.32
low: 0.001
 Debt To Equity 1.856
Debt To Equity QoQ 1508.354 %
Debt To Equity YoY 20454.153 %
Debt To Equity IPRWA high: 4.042
HIMS: 1.856
mean: 1.135
median: 0.903
low: -1.392
PRICE-BASED VALUATION
 Price To Book (P/B) 19.625
Price To Book QoQ 47.994 %
Price To Book YoY 67.84 %
Price To Book IPRWA HIMS: 19.625
high: 10.495
mean: 2.315
median: 1.731
low: -7.254
 Price To Earnings (P/E) 176.793
Price To Earnings QoQ 8.539 %
Price To Earnings YoY -45.665 %
Price To Earnings IPRWA high: 272.225
HIMS: 176.793
mean: 58.972
median: 38.169
low: -187.532
 PE/G Ratio 3.929
 Price To Sales (P/S) 20.269
Price To Sales QoQ 63.073 %
Price To Sales YoY 51.162 %
Price To Sales IPRWA high: 24.741
HIMS: 20.269
mean: 4.992
median: 3.24
low: 0.067
FORWARD MULTIPLES
Forward P/E 414.974
Forward PE/G 9.222
Forward P/S 132.734
EFFICIENCY OPERATIONAL
 Operating Leverage 7.663
ASSET & SALES
 Asset Turnover Ratio 0.393
Asset Turnover Ratio QoQ -46.309 %
Asset Turnover Ratio YoY -42.121 %
Asset Turnover Ratio IPRWA high: 1.071
HIMS: 0.393
median: 0.385
mean: 0.335
low: 0.001
 Receivables Turnover 79.66
Receivables Turnover Ratio QoQ -11.479 %
Receivables Turnover Ratio YoY 50.866 %
Receivables Turnover Ratio IPRWA HIMS: 79.66
high: 9.814
mean: 4.096
median: 2.867
low: 0.065
 Inventory Turnover 1.181
Inventory Turnover Ratio QoQ -46.588 %
Inventory Turnover Ratio YoY -29.585 %
Inventory Turnover Ratio IPRWA high: 9.67
mean: 5.29
median: 4.899
HIMS: 1.181
low: 0.412
 Days Sales Outstanding (DSO) 1.145
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 2.311
Cash Conversion Cycle Days QoQ -109.901 %
Cash Conversion Cycle Days YoY -108.648 %
Cash Conversion Cycle Days IPRWA high: 86.316
mean: 21.438
median: 15.818
HIMS: 2.311
low: -39.366
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.503
 CapEx To Revenue -0.092
 CapEx To Depreciation -4.808
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.5 B
 Net Invested Capital 1.5 B
 Invested Capital 1.5 B
 Net Tangible Assets 404.3 M
 Net Working Capital 1.1 B
LIQUIDITY
 Cash Ratio 4.205
 Current Ratio 4.979
Current Ratio QoQ 212.34 %
Current Ratio YoY 86.005 %
Current Ratio IPRWA high: 6.851
HIMS: 4.979
mean: 1.238
median: 0.838
low: 0.225
 Quick Ratio 4.459
Quick Ratio QoQ 237.05 %
Quick Ratio YoY 93.551 %
Quick Ratio IPRWA high: 6.687
HIMS: 4.459
mean: 0.907
median: 0.618
low: 0.306
COVERAGE & LEVERAGE
 Debt To EBITDA 28.084
 Cost Of Debt 0.226 %
 Interest Coverage Ratio 16.892
Interest Coverage Ratio QoQ -53.844 %
Interest Coverage Ratio YoY 142.276 %
Interest Coverage Ratio IPRWA high: 34.501
HIMS: 16.892
mean: 4.566
median: 3.159
low: -51.12
 Operating Cash Flow Ratio -0.06
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 62.841
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 110.559 %
 Revenue Growth -7.027 %
Revenue Growth QoQ -132.24 %
Revenue Growth YoY -152.156 %
Revenue Growth IPRWA high: 17.881 %
median: 4.575 %
mean: 3.881 %
HIMS: -7.027 %
low: -32.565 %
 Earnings Growth 45.0 %
Earnings Growth QoQ -45.0 %
Earnings Growth YoY 125.0 %
Earnings Growth IPRWA high: 250.0 %
HIMS: 45.0 %
median: -19.556 %
mean: -22.269 %
low: -291.304 %
MARGINS
 Gross Margin 76.39 %
Gross Margin QoQ 3.939 %
Gross Margin YoY -6.036 %
Gross Margin IPRWA high: 88.057 %
HIMS: 76.39 %
median: 26.662 %
mean: 26.179 %
low: -9.108 %
 EBIT Margin 4.905 %
EBIT Margin QoQ -50.354 %
EBIT Margin YoY 40.384 %
EBIT Margin IPRWA high: 35.873 %
mean: 7.362 %
HIMS: 4.905 %
median: 2.773 %
low: -48.909 %
 Return On Sales (ROS) 4.905 %
Return On Sales QoQ -50.354 %
Return On Sales YoY 40.384 %
Return On Sales IPRWA high: 31.023 %
median: 8.725 %
mean: 8.29 %
HIMS: 4.905 %
low: -49.228 %
CASH FLOW
 Free Cash Flow (FCF) -69.43 M
 Free Cash Flow Yield -0.629 %
Free Cash Flow Yield QoQ -191.557 %
Free Cash Flow Yield YoY -155.961 %
Free Cash Flow Yield IPRWA high: 12.561 %
mean: 1.778 %
median: 1.538 %
HIMS: -0.629 %
low: -16.999 %
 Free Cash Growth -238.72 %
Free Cash Growth QoQ 1403.369 %
Free Cash Growth YoY -179.466 %
Free Cash Growth IPRWA high: 390.254 %
mean: -44.797 %
median: -52.4 %
HIMS: -238.72 %
low: -652.057 %
 Free Cash To Net Income -1.633
 Cash Flow Margin -3.017 %
 Cash Flow To Earnings -0.387
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 3.07 %
Return On Assets QoQ -50.396 %
Return On Assets YoY 7.193 %
Return On Assets IPRWA high: 5.204 %
HIMS: 3.07 %
median: 0.951 %
mean: 0.949 %
low: -16.328 %
 Return On Capital Employed (ROCE) 1.665 %
 Return On Equity (ROE) 0.076
Return On Equity QoQ -16.151 %
Return On Equity YoY 105.607 %
Return On Equity IPRWA high: 0.111
HIMS: 0.076
median: 0.023
mean: 0.022
low: -0.486
 DuPont ROE 7.645 %
 Return On Invested Capital (ROIC) 1.378 %
Return On Invested Capital QoQ -84.018 %
Return On Invested Capital YoY -128.243 %
Return On Invested Capital IPRWA high: 7.951 %
median: 1.963 %
mean: 1.556 %
HIMS: 1.378 %
low: -22.946 %

Six-Week Outlook

Expect elevated two-way volatility driven by regulatory headlines, given recent FTC and FDA attention, and the stock’s high beta, which amplifies headline impact. Technicals skew bearish: momentum indicators and moving-average relationships favor lower near-term price bias, while the negative MRO signals latent upside if momentum indicators stabilize or DI+ reverses higher.

Swing traders should anticipate headline-driven intraday moves rather than steady trends; any durable momentum shift will require MACD stabilization and a rising RSI accompanied by DI+ support. Balance-sheet resilience limits tail liquidity risk, but stretched valuation multiples and the company’s regulatory exposure leave directional conviction uncertain until clearer regulatory outcomes or consistent margin recovery materialize.

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE:HIMS) designs a telehealth platform that connects consumers with licensed healthcare professionals, offering a range of health and wellness solutions. Based in San Francisco, California, the company serves markets in the United States, the United Kingdom, and beyond. Hims & Hers provides access to both prescription and over-the-counter products, addressing needs in areas such as sexual health, skincare, hair care, and general wellness. The company’s platform facilitates the acquisition of prescription medications through a subscription model, enhancing the management of healthcare needs. Its product line includes items like melatonin supplements, skincare products, and sexual wellness solutions. For hair care, Hims & Hers offers shampoos, conditioners, and treatments such as minoxidil. Through wholesale partnerships, Hims & Hers expands the availability of its curated health and wellness products. The company emphasizes quality care by offering medical consultations and follow-up services, ensuring a comprehensive healthcare experience. By utilizing technology, Hims & Hers Health empowers individuals to manage their health conveniently from home.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.